Treatment of atopic dermatitis with ruxolitinib cream significantly improved patient-reported measures of work productivity and daily activity impairment.

Using a human capital approach, incremental annual indirect cost savings for patients applying 0.75% or 1.5% ruxolitinib cream were estimated to be $5302 and $4228, respectively.